CEACAM5 and neoplasm: Rothe et al. [54] designed a fusion protein composed of human ULBP2 and a single chain derived from an antibody targeting tumor carcinoembryonic antigen (CEA) that could redirect NK cells to malignant cells by binding to tumor cells and NK cells, and triggered NK cell-mediated target cell killing in vitro.